FDA Approves ARBLI — Scienture LLC

# FDA Approves Scienture LLC's ARBLI (Losartan Potassium) for Oral Use The U.S. Food and Drug Administration has approved Scienture LLC's ARBLI (losartan potassium) oral formulation, expanding the competitive landscape in the widely-used antihypertensive market dominated by established generic and brand-name alternatives. The approval of NDA218772 positions Scienture to capture market share in the multi-billion-dollar losartan segment, where pricing pressure and generic competition remain significant factors for manufacturers and payers alike.